Meeting
2023 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) monitoring in patients with breast cancer receiving neoadjuvant palbociclib and endocrine therapy: A secondary analysis of the NeoRHEA phase 2 study.
Authors
Alexandra Stanciu
Institut Jules Bordet, Bruxelles, Belgium
Alexandra Stanciu , Andreas Papagiannis , Christodoulos Pipinikas , Nathan Campbell , Mariana Brandão , Frederic Cailleux , Elisa Agostinetto , Lieveke Ameye , Marianne Paesmans , Tatiana Besse-Hammer , Ahmad Awada , Martine J. Piccart-Gebhart , Christos Sotiriou , Patrick Neven , Francois P. Duhoux , Nitzan Rosenfeld , Peter Vuylsteke , Michail Ignatiadis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT03065621
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 601)
DOI
10.1200/JCO.2023.41.16_suppl.601
Abstract #
601
Poster Bd #
431
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Evaluating metrics of circulating tumor DNA response and progression using a high sensitivity tumor-agnostic assay in metastatic HR+/HER2- breast cancer receiving endocrine therapy and a CDK4/6-inhibitor.
First Author: Mitchell Elliott
Poster
2024 ASCO Annual Meeting
Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial.
First Author: Joan Albanell
First Author: Jacqueline Shaw
Poster
2022 ASCO Annual Meeting
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer.
First Author: Sara A. Hurvitz